Randomized and nonrandomized clinical studies - Statistical considerations

被引：2
|
作者：
Baker, SG [1 ]
机构：
[1] NCI, Div Canc Prevent, Biometry Res Gr, Bethesda, MD 20892 USA
[2] Johns Hopkins Med Inst, Dept Anesthesiol Crit Care Med, Baltimore, MD USA
来源：
ANESTHESIOLOGY | 2000年 / 92卷 / 04期
关键词：
anesthesia; general; observational studies; paired availability design; regional;
D O I：
10.1097/00000542-200004000-00006
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
引用
收藏
页码：928 / 930
页数：3
相关论文
共 50 条
  • [1] Statistical and regulatory issues in nonrandomized medical device clinical studies
    Lilly, Heng Li
    Yue, Lilly Q.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (01) : 20 - 30
  • [2] Randomized and nonrandomized studies: Complementary or competing?
    Pandis, Nikolaos
    Tu, Yu-Kang
    Fleming, Padhraig S.
    Polychronopoulou, Argy
    AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2014, 146 (05) : 633 - 640
  • [3] Interpretation of clinical studies in electronilysiology: statistical considerations for the clinician
    Chieng, David
    Finch, Sue
    Sugumar, Hariharan
    Taylor, Andrew J.
    Reid, Chris
    Kalman, Jonathan M.
    Kistler, Peter M.
    EUROPACE, 2021, 23 (06): : 821 - 827
  • [4] Statistical considerations on clinical studies with special reference to phase-3 clinical studies
    Talamini, R
    TUMORI, 1999, 85 (03) : S53 - S54
  • [5] Evidence in transplantation: Randomized versus nonrandomized studies
    Morris, Peter J.
    Monaco, Anthony P.
    TRANSPLANTATION, 2008, 86 (01) : 16 - 17
  • [6] Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies
    Yue, Lilly Q.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (01) : 1 - 13
  • [7] Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials
    Haijun Ma
    Chunlei Ke
    Qi Jiang
    Steven Snapinn
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 957 - 965
  • [8] Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials
    Ma, Haijun
    Ke, Chunlei
    Jiang, Qi
    Snapinn, Steven
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (06) : 957 - 965
  • [9] Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission
    Yumiko Asami
    Jean Pan
    MyungShin Oh
    Akira Sato
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1134 - 1137
  • [10] Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission
    Asami, Yumiko
    Pan, Jean
    Oh, MyungShin
    Sato, Akira
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1134 - 1137
12345